![]() |
|
|
Vol. 295, Issue 3, 1051-1060, December 2000
-Aminobutyric AcidA Receptor
Merck Sharp & Dohme Research Laboratories, Neuroscience Research
Centre, Terlings Park, Eastwick Road, Harlow, Essex, United Kingdom
(G.R.D., K.W., A.S., G.M., P.J.B., R.M.M.); and Merck Sharp & Dohme
Research Laboratories, Rahway, New Jersey (J.M.S., P.T.M.)
Twenty-five avermectin analogs were assessed in a mouse seizure model.
The ED50 against pentylenetetrazole-induced tonic
seizures ranged from 0.48 mg/kg (L-676,893) to >160 mg/kg (L-685,869)
cf. 0.26 mg/kg for diazepam. Although avermectins are without acute toxic effects, they have been historically shown to have relative low
LD50 values in mammals. The mechanisms involved in the
anticonvulsant effect and the toxicity were investigated. A series of
avermectin analogs displaced [3H]ivermectin binding to
rat brain membranes and recombinant GABAA receptors
(
1
3
2-subtype) with the same affinities, strongly suggesting
that [3H]ivermectin labels the GABAA receptor
in rodent brain. Avermectins, which were anticonvulsant, were also
potent inhibitors of [3H]ivermectin binding in rat brain.
However, the rank order for anticonvulsant activity did not parallel
the rank order for affinity at the [3H]ivermectin site
and it was reasoned that avermectins may have differential affinity or
efficacy at subtypes of the GABAA receptor. All the active
compounds tested potentiated the effects of GABA at recombinant
GABAA receptors in oocytes and at native cortical GABAA receptors and the efficacy of avermectins at the
GABAA receptor correlated best with their anticonvulsant
potency. Although avermectins weakly inhibited
[3H]strychnine binding in rat spinal cord, and inhibited
glycine responses on primary cultured cortical neurons, activity at
glycine receptors did not correlate with either anticonvulsant activity or toxicity. Because both anticonvulsant activity and toxicity correlated best with activity at GABAA receptors, it is
unlikely that these effects can be separated, which may contraindicate the potential use of avermectins as anticonvulsants.
This article has been cited by other articles:
![]() |
J. W. Lynch Molecular Structure and Function of the Glycine Receptor Chloride Channel Physiol Rev, October 1, 2004; 84(4): 1051 - 1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Neff, K. R. Robertson, A. K. Wong, N. Safra, K. W. Broman, M. Slatkin, K. L. Mealey, and N. C. Pedersen From the Cover: Breed distribution and history of canine mdr1-1{Delta}, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage PNAS, August 10, 2004; 101(32): 11725 - 11730. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Priel and S. D. Silberberg Mechanism of Ivermectin Facilitation of Human P2X4 Receptor Channels J. Gen. Physiol., February 23, 2004; 123(3): 281 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Shan, J. L. Haddrill, and J. W. Lynch Ivermectin, an Unconventional Agonist of the Glycine Receptor Chloride Channel J. Biol. Chem., April 13, 2001; 276(16): 12556 - 12564. [Abstract] [Full Text] [PDF] |
||||